Cargando…
Novel retinoblastoma treatment avoids chemotherapy: the effect of optimally timed combination therapy with angiogenic and glycolytic inhibitors on LH(BETA)T(AG) retinoblastoma tumors
PURPOSE: The purpose of this study was to evaluate the effect of optimally timed combination treatment with angiogenic and glycolytic inhibitors on tumor burden, hypoxia, and angiogenesis in advanced retinoblastoma tumors. METHODS: LH(BETA)T(AG) mice (n =30) were evaluated. Mice were divided into 5...
Autores principales: | Houston, Samuel K, Piña, Yolanda, Murray, Timothy G, Boutrid, Hinda, Cebulla, Colleen, Schefler, Amy C, Shi, Wei, Celdran, Magda, Feuer, William, Merchan, Jaime, Lampidis, Ted J |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3037041/ https://www.ncbi.nlm.nih.gov/pubmed/21339806 http://dx.doi.org/10.2147/OPTH.S15179 |
Ejemplares similares
-
Advanced retinoblastoma treatment: targeting hypoxia by inhibition of the mammalian target of rapamycin (mTOR) in LH(BETA)T(AG) retinal tumors
por: Piña, Y, et al.
Publicado: (2011) -
Retinoblastoma treatment: impact of the glycolytic inhibitor 2-deoxy-d-glucose on molecular genomics expression in LH(BETA)T(AG) retinal tumors
por: Piña, Yolanda, et al.
Publicado: (2012) -
Lack of Effect of SU1498, an Inhibitor of Vascular Endothelial Growth Factor Receptor-2, in a Transgenic Murine Model of Retinoblastoma
por: Cebulla, C.M, et al.
Publicado: (2008) -
Recent advancements in the management of retinoblastoma and uveal melanoma
por: Schefler, Amy C, et al.
Publicado: (2018) -
Recent advancements in the management of retinoblastoma and uveal melanoma
por: Schefler, Amy C, et al.
Publicado: (2021)